Exelixis (EXEL) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Powered by 
Analysis
Exelixis (EXEL) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 0.75% |
| Apr 3, 2026 | -13.93% |
| Jan 2, 2026 | 26.32% |
| Oct 3, 2025 | 4.72% |
| Jul 4, 2025 | 15.81% |
| Apr 4, 2025 | 14.12% |
| Jan 3, 2025 | 18.55% |
| Sep 27, 2024 | -47.83% |
| Jun 28, 2024 | 505.93% |
| Mar 29, 2024 | -56.36% |
| Dec 29, 2023 | 8,114.99% |
| Sep 29, 2023 | -98.72% |
| Jun 30, 2023 | 102.80% |
| Mar 31, 2023 | 232.66% |
| Dec 30, 2022 | -141.21% |
| Sep 30, 2022 | 3.59% |
| Jul 1, 2022 | 3.06% |
| Apr 1, 2022 | -27.94% |
| Dec 31, 2021 | 149.10% |
| Oct 1, 2021 | -60.24% |